Document is current

Article History

Received: 4 June 2023

Accepted: 21 October 2023

First Online: 26 October 2023

Declarations

:

: Dr. Iihara reported receiving personal fees from Taiho, Chugai, Yakult, Astellas, Eli Lilly, Daiichi Sankyo, AstraZeneca, Nippon Kayaku, Ono, and Nippon Boehringer Ingelheim and is receiving consulting fees to their institution from Taiho and Eisai outside the submitted work. Dr. Suzuki is receiving personal fees from Toa Eiyo, Asahi Kasei, Daiichi Sankyo, Pfizer, Eisai, Nippon Shinyaku, Celltrion Healthcare Japan, Otsuka, Sandoz, Tsumura, Nipro, Taiho, Kyowa-Kirin, Nippon Chemiphar, Japan Blood Products Organization, Takeda, and Nippon Boehringer Ingelheim and is receiving grants to their institution from Nippon Kayaku, Asahi Kasei, Chugai, Taiho, Daiichi Sankyo, Japan Blood Products Organization, Mochida, and Sun Pharma outside the submitted work.

: This study was conducted in accordance with the guidelines for human studies adopted by the ethics committee of Gifu University Graduate School of Medicine and approved by the Japanese government (Institutional Review Board approval no. 2022–286).

: Given the retrospective nature of the study, obtaining the informed consent was waived.